Sikkerhed og præstationer af LINEA-hjertepacingledningen optimeret til implantation i interventrikulært septum (STARLIGHT)
Sikkerhed og præstationer for LINEA-kardiopacemakerledningen optimeret til implantation i interventrikulært septum
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Antoine Guihard
- Telefonnummer: +33 1 46 01 33 20
- E-mail: antoine.guihard@cf.microport.com
Studiesteder
-
-
-
Ghent, Belgien
- Rekruttering
- Ghent University Hospital
-
Kontakt:
- Jan De Pooter
- E-mail: jadpoote.depooter@ugent.be
-
-
-
-
-
Annecy, Frankrig
- Rekruttering
- Centre Hospitalier Annecy Genevois
-
Kontakt:
- Pierre Frey
- E-mail: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, Frankrig
- Rekruttering
- CHU Clermont-Ferrand
-
Kontakt:
- Pierre-Antoine Catalan
- E-mail: pacatalan@chu-clermontferrand.fr
-
Grenoble, Frankrig
- Rekruttering
- CHU Grenoble
-
Kontakt:
- Adrien Carabelli
- E-mail: acarabelli@chu-grenoble.fr
-
Montpellier, Frankrig
- Rekruttering
- Clinique du Millénaire
-
Kontakt:
- Nicolas Clémenty
- E-mail: nicolas.clementy@gmail.com
-
Rouen, Frankrig
- Rekruttering
- CHU Rouen Hôpital Charles Nicolle
-
Kontakt:
- Raphaël Al Hamoud
- E-mail: raphael.al-hamoud@chu-rouen.fr
-
Tours, Frankrig
- Rekruttering
- Hôpital Trousseau
-
Kontakt:
- Arnaud Bisson
- E-mail: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Italien
- Rekruttering
- Ospedale Maggiore della Carità - AO Univ.
-
Kontakt:
- Gabriele Dell'Era
- E-mail: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Italien
- Rekruttering
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Kontakt:
- Gianluca Mirizzi
- E-mail: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Portugal
- Rekruttering
- ULS de Coimbra
-
Kontakt:
- João Ferreira
- E-mail: joaoaferreira29@gmail.com
-
Lisbon, Portugal
- Rekruttering
- ULS Santa Maria
-
Kontakt:
- Nelson Cunha
- E-mail: nelsoncunha@campus.ul.pt
-
-
-
-
-
Girona, Spanien
- Rekruttering
- Hospital Universitari de Girona Doctor Josep Trueta
-
Kontakt:
- María Emilce Trucco
- E-mail: metrucco.girona.ics@gencat.cat
-
Granada, Spanien
- Rekruttering
- Hospital Universitario Virgen de las Nieves
-
Kontakt:
- Manuel Molina
- E-mail: manuel.molina.lerma@gmail.com
-
Valencia, Spanien
- Rekruttering
- Hospital Universitari i Politècnic La Fe
-
Kontakt:
- Óscar Cano
- E-mail: oscape13@hotmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: LINEA kardiak pacemaker-ledning
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Tidsramme: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Tidsramme: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Tidsramme: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Tidsramme: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Tidsramme: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Tidsramme: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Tidsramme: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Tidsramme: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Tidsramme: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Tidsramme: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- LLAI01 - STARLIGHT
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .